CMS Okays Payment for Novel AI Prostate Test

Medicare will now cover an AI-based test for prostate cancer that predicts which men will benefit from androgen deprivation therapy. The Centers for Medicare & Medicare Services approved the payment rate for ArteraAI as a clinical diagnostic test. The test improves risk stratification and personalizes treatment. It combines a patient’s clinical and pathologic information into an algorithm and analyzes prostate biopsies to estimate a patient’s risk of developing metastasis or dying from prostate cancer. The test is 80% accurate as a prognostic test and spares about two-thirds of men from the side effects of hormone therapy. It provides detailed, personalized information to help patients make confident decisions about prostate cancer treatment.

Source link

error: Content is protected !!